Better Therapeutics, Inc. (NASDAQ:BTTX) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET

Company Participants

Mark Heinen - Chief Financial Officer

Frank Karbe - President and CEO

Diane Gomez - Chief Commercial Officer

Mark Berman - Chief Medical Officer

Conference Call Participants

Thomas Flaten - Lake Street Capital Markets

Keay Nakae - Chardan

Rahul Rakhit - LifeSci Capital

Operator

Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode. After the speakers' presentation, there’ll be a question-and-answer session. [Operator Instructions]. And please be advised today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Mark Heinen, Chief Financial Officer.

Mark Heinen

Thank you, operator. Good morning, everyone, and welcome to the Better Therapeutics conference call. Our press release was issued this morning and can be found in the Investors section of our corporate website, bettertx.com.

Joining me on the call today is Frank Karbe, our President and Chief Executive Officer; Dr. Mark Berman, our Chief Medical Officer; and Diane Gomez-Thinnes, our Chief Commercial Officer. During today's call, we will provide a business update and a financial overview of the second quarter of 2023. A Q&A session will follow our prepared remarks.

Before we begin, I'd like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans, and expectations that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events and results may differ materially from those expressed or implied by any forward-looking statement.

With that, I'll pass the call over Frank Karbe. Frank?

Frank Karbe

Thank you, Mark, and good morning, everyone. Thanks for joining us on the call today. I will begin with a brief recap of the exciting news we shared recently regarding FDA authorization.

In July, AspyreRx, formerly known as BT-001, received FDA authorization as a Class 2 medical device indicated to treat adults with Type 2 diabetes. This marks the culmination of eight years of development involving more than 6,000 participants in studies of increasing rigor.

And with this FDA authorization, a new regulatory class of digital therapeutics has been established with AspyreRx being the first prescription-only digital therapeutic treatment to provide cognitive behavioral therapy, or CBT, to adult patients with Type 2 diabetes.